Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02425891 · OUTCOME

Percentage of Participants With at Least One Adverse Event

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) · Source last updated 2022-07-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
Baseline up to to the data cutoff date: 31 August 2021 (up to approximately 74 months)

What was measured

Percentage of participants with at least one adverse event.

Analysis population: The safety-evaluable population is defined as participants who received any amount of any study drug.

Groups in this outcome

Atezolizumab Plus Nab-Paclitaxel

Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.

Placebo Plus Nab-Paclitaxel

Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab Plus Nab-Paclitaxel460
Placebo Plus Nab-Paclitaxel430

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab Plus Nab-Paclitaxel99.3Not reportedNot reportedNot reportedNot reported
Placebo Plus Nab-Paclitaxel97.9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        99.3
      2. group Id
        OG001
        value
        97.9
denoms
  1. counts
    1. group Id
      OG000
      value
      460
    2. group Id
      OG001
      value
      430
    units
    Participants
description
Percentage of participants with at least one adverse event.
groups
  1. description
    Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
    id
    OG000
    title
    Atezolizumab Plus Nab-Paclitaxel
  2. description
    Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
    id
    OG001
    title
    Placebo Plus Nab-Paclitaxel
param Type
NUMBER
population Description
The safety-evaluable population is defined as participants who received any amount of any study drug.
reporting Status
POSTED
time Frame
Baseline up to to the data cutoff date: 31 August 2021 (up to approximately 74 months)
title
Percentage of Participants With at Least One Adverse Event
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice